RxTrials Institute Drug Pipeline Alert
March 12, 2008 | Vol. 6 No. 11
Antibiotic Enters Phase I Development
Affinium has begun dosing healthy subjects in a Phase I study of AFN-1252 to treat susceptible and resistant staphylococcal infections.
The study will evaluate the safety, tolerability and pharmacokinetics of a single escalating dose of the product.
AFN-1252 is an investigational antibiotic with a high potency against all drug-resistant phenotypes of staphylococci, including hospital- and community-acquired methicillin-resistant Staphylococcus aureus, according to Affinium.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.